Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16471273 | 0.87 | GAA (0.63) | GAAMEN1GFERKMT2AMAPT | |
| SCHEMBL16471272 | 0.85 | GAA (0.61) | GAAMEN1GFERKMT2AMAPT | |
| SCHEMBL18856585 | 0.85 | JAK2 (0.73) | GAAMEN1GFERKMT2AJAK2 | |
| SCHEMBL16014502 | 0.84 | GAA (0.59) | GAAMEN1GFERKMT2AMAPT | |
| SCHEMBL18856773 | 0.84 | GAA (0.59) | GAAMEN1GFERKMT2AMAPT | |
| SCHEMBL15555851 | 0.83 | JAK2 (0.76) | GAAMEN1GFERKMT2AJAK2 | |
| SCHEMBL17402836 | 0.82 | — | — | |
| SCHEMBL20194880 | 0.81 | JAK2 (0.64) | GAAMEN1GFERKMT2AJAK2 | |
| SCHEMBL16014481 | 0.81 | GAA (0.65) | GAAMEN1GFERKMT2AJAK2 | |
| SCHEMBL15606404 | 0.81 | GAA (0.71) | GAAMEN1GFERKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GAA 88/4885MEN1 4686/4885GFER 3631/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GAA 88/4885MEN1 4686/4885GFER 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.